Compare Merck & Co., Inc. (MRK) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while YieldMax TSLA Option Income Strategy ETF trades at $25.63. The key difference: Merck & Co., Inc. pays a 2.73% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MRK | TSLY | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $129.52 | $48.25 |
52-Week Low | $77.60 | $25.07 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
TSLY, the YieldMax TSLA Option Income Strategy ETF, trades at $25.07, down 2.57% today amid a bearish technical signal. The ETF generates high income through weekly distributions, with recent dividends ranging from $0.26 to $0.52 per share, but faces criticism for capping upside during Tesla rallies. Its strategy relies on synthetic Tesla exposure and covered call overlays, producing an annualized yield near 52.65%, though distributions are largely return of capital.
The outlook is cautious due to structural limitations that sacrifice capital appreciation for income, with risks including volatility from Tesla's performance and option strategy complexity. Investors prioritizing yield may find value, but those seeking growth could underperform Tesla's equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
